No abstract

No abstract

Cancer is a major public health problem in many countries of the world. It is currently the second leading cause of death in the United States and is expected to surpass heart diseases as the leading cause of death in the next few years (1). Therefore there is a continuous need for the development of new compounds with potential anticancer activity. Carcinogenesis is a complicated process, usually developing over years. The process may be caused by external factors (responsible for up to 80% of cases), and certain genetic factors. In some types of cancer, the overexpression of specific kinases is one of the basic factors of neoplastic transformation. One example is chronic myeloid leukemia (CML), which is a result of genetic mutation leading to formation of pathological BCR-ABL gene encoding a p210 protein, which shows abnormal, increased tyrosine kinase activity. It is assumed that expression of BCR-ABL is an essential factor for neoplastic transformation in CML. The milestone in the treatment of this type of cancer was introduction of selective kinase inhibitors. In the case of CML, tyrosine kinase inhibitor ñ Imatinib (Glivec) due to the high efficacy and good tolerability, it became the ìgold standardî treatment of patients with CML (2).

A variety of novel, chiral 4‐arylpyrrolopyrazine derivatives (II) are synthesized and evaluated for their anticonvulsant activity.

In this study, we designed and synthesized sixteen new derivatives of 7-amino-4-methylquinolin-2(1H)-one with potential anticancer activity. The structures of synthesized compounds were confirmed by 1H and 13 C NMR. The activity of novel substances was evaluated by cell viability assay and wound healing assay. In vitro tests for series of sixteen novel compounds were performed. The results showed that examined compounds are selective for a cancer cells, but their activity for various types of cancer is different. Three of the new compounds presented the ability to inhibit cells migration. The novel compounds constitute a good starting point for further studies and optimization of structure for new therapeutically effective anti-cancerous drugs. Seven compounds, which showed the highest rate of cell inhibition, were selected for further studies.